Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

Autor: Diana De Ronchi, Jacques Berlo, Raffaella Calati, Joseph Zohar, Daniel Souery, Yves Lecrubier, Siegfried Kasper, Roser Sens-Espel, Sylvie Linotte, Alessandro Serretti, Julien Mendlewicz, Patricia Lienard, Joseph Bollen, Isabelle Massat
Přispěvatelé: Serretti A., Calati R., Massat I., Linotte S., Kasper S., Lecrubier Y., Sens-Espel R., Bollen J., Zohar J., Berlo J., Lienard P., De Ronchi D., Mendlewicz J., Souery D., Serretti, A, Calati, R, Massat, I, Linotte, S, Kasper, S, Lecrubier, Y, Sens-Espel, R, Bollen, J, Zohar, J, Berlo, J, Lienard, P, De Ronchi, D, Mendlewicz, J, Souery, D
Rok vydání: 2009
Předmět:
Zdroj: International Clinical Psychopharmacology. 24:250-256
ISSN: 0268-1315
DOI: 10.1097/yic.0b013e32832e5b0d
Popis: Cytochrome P450 genes are involved in the metabolism of antidepressants and could influence treatment response. The aim of this study was to investigate the role of allelic variations of the cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes in antidepressant treatment response and remission rates. Two hundred and seventy-eight patients affected by major depression, responders (N=81) and nonresponders (N=197) to at least one adequate antidepressant treatment, were recruited with a multicentre design for resistant depression and genotyped for all relevant variations. None of the considered metabolic profiles (e.g. poor, intermediate, extensive and ultrarapid metabolizers) was found to be associated with either response or remission rates. In conclusion, the investigated cytochrome genes do not seem to play a major role in antidepressant response in the present sample of depressive patients. Nevertheless, methodological and sample size limitations of this study do not allow definitive conclusions. Int Clin Psychopharmacol 24:250-256 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Databáze: OpenAIRE